Article
After bruising rejection, bluebird and Bristol Myers Squibb land ide-cel priority review. But will
Rating:
0.0
Views:
175
Likes:
1
Library:
1
With the clock all but up, the FDA accepted and handed priority review to Bristol Myers Squibb and bluebird bio's BCMA CAR-T, keeping a narrow window
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value